Introduction
============

Zinc is an essential trace element with indispensable roles in numerous processes in the human body.[@b1-nmi-8-2015-007],[@b2-nmi-8-2015-007] It has various functions including structural, catalytic, and regulatory roles. A wide range of fundamental physiological processes require zinc including protein synthesis, cellular signaling, and modulation of transporters as well as regulation of enzymes, apoptosis, and transcription factors. Proteomic analysis reveals that approximately 4%--10% of proteins have zinc-binding motifs.[@b3-nmi-8-2015-007] Suboptimal levels of zinc in physiological systems will likely have several negative biological and clinical effects; thus, zinc has widespread public health importance.

Zinc uptake and excretion is homeostatically regulated by transport of zinc ions actively across biological membranes.[@b2-nmi-8-2015-007] Zinc transporters contribute to the regulation of zinc homeostasis by coordinating extracellular or organellar zinc influx and cellular zinc efflux or its sequestration into intracellular organelles. Two families of mammalian zinc transporters exist: ZnT (solute-linked carrier 30 \[SLC30\]) and Zrt-Irt-like protein (ZIP or solute-linked carrier 39 \[SLC39\]). ZnTs reduce intracellular zinc concentration by transporting zinc out of the cytoplasm or into vesicles.[@b4-nmi-8-2015-007]--[@b6-nmi-8-2015-007] In contrast to the function of ZnTs, ZIP transporters increase intracellular zinc concentration by facilitating zinc transport into cytosol either from extracellular space or from the lumen of intracellular compartments.[@b7-nmi-8-2015-007] Similarly, metallothionein (MT), a ubiquitous cellular zinc storage protein, regulates intracellular zinc by releasing/binding ions through the reduction of the thiol group in the MT protein.[@b5-nmi-8-2015-007],[@b8-nmi-8-2015-007]

Zinc has regulatory roles in gene expression leading to the suggestion that specific genomic changes and functional outcomes may be used to assess zinc status. However, this suggestion is largely unexplored and is a promising area to investigate for potential biomarkers to assess zinc status.[@b9-nmi-8-2015-007] Some studies showed significant change in the mRNA abundance of selected zinc transporters and MT from peripheral blood mononuclear cells (PBMCs) and from leukocyte subsets in cell culture studies and zinc-supplemented humans.[@b10-nmi-8-2015-007]--[@b13-nmi-8-2015-007]

An investigation of mRNA for eight zinc transporters in PBMCs of healthy men and women (*n* = 40) with an adequate zinc intake revealed considerable variation in the relative expression of zinc transporter mRNA, with *ZnT1*, *ZnT7*, and *ZIP1* being the most abundantly expressed.[@b14-nmi-8-2015-007] Similarly, a comparison of the relative expression of nine zinc transporter genes in human monocytes, T lymphocytes, and granulocytes from blood samples (*n* = 3) indicated major differences in zinc transporter transcript abundance.[@b12-nmi-8-2015-007] A comparison study of the expression of *ZnT1--8* and *ZIP1--8* in visceral and subcutaneous adipose fat from lean and obese individuals revealed different expression levels, but all tested zinc transporter mRNAs were detectable.[@b15-nmi-8-2015-007]

The search to identify specific biomarkers of zinc status has been ongoing and to date largely unsuccessful.[@b12-nmi-8-2015-007],[@b16-nmi-8-2015-007] However, assessing the molecular aspects of the cellular biology of zinc using mRNA abundance of zinc transporter proteins and MT in response to zinc supplementation has been suggested as a possible technique for the investigation of zinc status.[@b8-nmi-8-2015-007],[@b17-nmi-8-2015-007]

Real-time quantitative polymerase chain reaction (qPCR) is a highly sensitive and reproducible method that can be useful for detecting changes in gene expression, even from samples collected during interventional trials or field studies wherein biological samples may be limiting.[@b10-nmi-8-2015-007],[@b12-nmi-8-2015-007] Collection of PBMCs is relatively simple, and these cells may represent a readily available tissue source for the exploration of human zinc transporter mRNA expression.[@b14-nmi-8-2015-007]

Despite an appreciation for the prevalence of zinc deficiency in humans, relatively few zinc depletion--repletion studies or studies in populations with inadequate zinc intakes have been conducted to examine the effectiveness of zinc supplementation on increasing zinc status in zinc-deficient individuals.[@b14-nmi-8-2015-007],[@b18-nmi-8-2015-007] Thus, based on previous human study outcomes,[@b12-nmi-8-2015-007],[@b14-nmi-8-2015-007],[@b15-nmi-8-2015-007] the objectives of the current study were to evaluate the effect of zinc supplementation on the abundance of mRNA encoding the zinc transporters *ZnT1*, *ZIP3*, *ZIP4*, and *ZIP8* and the zinc-responsive MT protein encoded by *MT1* mRNA as well as plasma zinc concentrations in apparently healthy adult women. Women were selected because their limited diets and frequent child bearing make them particularly vulnerable to micronutrient deficiencies.[@b19-nmi-8-2015-007],[@b20-nmi-8-2015-007] We hypothesized that there will be significant differences in the mRNA abundance of *MT* and zinc transporters *ZnT1*, *ZIP3*, *ZIP 4*, *ZIP8* as well as plasma zinc due to zinc supplementation for 23 days.

Experimental Section
====================

Participants
------------

This study was conducted from June to July 2012 in a rural community (Finchawa) in Sidama zone, southern Ethiopia. The diet in rural Sidama is composed of cereals (mainly maize), kocho, a fermented product of the plant *Enset ventricosum*, kale and kidney beans with very low intake of animal source foods. Our previous studies have shown these food items had low concentrations of zinc and high phytate to zinc molar ratios.[@b21-nmi-8-2015-007] Several prior studies in rural Sidama indicated the presence of zinc deficiency. A zinc assessment study found that all the pregnant women (*n* = 99) in the study had inadequate zinc intake, with a very low median zinc intake of 5.0 mg Zn/d.[@b20-nmi-8-2015-007],[@b22-nmi-8-2015-007] Also, a cross-sectional study of pregnant women (*n* = 700) in 2011 confirmed the presence of zinc deficiency in the same region.[@b23-nmi-8-2015-007] To our knowledge, there has been no zinc intervention program in the study area.

A list of eligible adult women in the community (*n* = 1349) was obtained through the Community Health Center. The sample size was calculated with the inputs of 95% confidence level and 85% power for repeated measures using G-Power version 3.1.[@b24-nmi-8-2015-007] Forty-eight adult women were selected randomly using SPSS software version 20.0 (IBM-SPSS, Armonk, NY, USA) from the provided list. Women who were pregnant, breast-feeding, under- or overweight (body mass index \[BMI\] \<18.5 or \>24.9), or who self-reported illness within 1 week prior to the start of the study were excluded. To determine each participant's BMI for screening, anthropometric measurements were taken in duplicate using a standardized protocol and calibrated equipment.[@b25-nmi-8-2015-007] Seventeen women who were below 18.5 BMI and one woman above 24.9 BMI were excluded and replaced by a random selection from the original list. All eligible participants gave informed consent to participate in the study. The research procedure complied with the principles of the Declaration of Helsinki. The study protocol was approved by the Institutional Review Board of the Oklahoma State University. In Ethiopia, Hawassa University Ethical Committee, the Ministry of Science and Technology National Research Ethics Review Committee, and the Food and Medicine Administration and Control Authority approved the study.

Study design
------------

The study was a double-blind placebo-controlled zinc supplementation trial. Forty-eight adult women were randomly assigned either to placebo or zinc supplementation groups using SPSS software version 20.0 (IBM-SPSS). The principal investigator and all research assistants as well as the participants were blinded to the treatment. Baseline data were collected, and then for 23 days each participant consumed a zinc supplement capsule (20 mg of Zn as ZnSO~4~) or a placebo capsule (lactose monohydrate) (Perry Pharmacy, Perry, OK, USA). The duration of the study and the interval for sample collection were comparable to similar zinc supplementation studies.[@b12-nmi-8-2015-007],[@b26-nmi-8-2015-007] The zinc supplement was well below the upper level of 40 mg/d of zinc.[@b27-nmi-8-2015-007],[@b28-nmi-8-2015-007] Supplement or placebo was consumed daily between the hours of 8:00 and 10:00 am under the direct supervision of the PI and compliance was 100%. No adverse effects were reported.

Questionnaire administration
----------------------------

At baseline, demographic, socioeconomic, and dietary data were collected using a structured questionnaire. Dietary diversity (DD) was assessed for the 24 h prior to interview by asking participants if they had taken any food from 12 predefined food categories (cereals, roots and tubers, vegetables, fruits, meat, eggs, fish and seafood, pulses \[legumes/nuts\], milk and milk products, oil and fats, sweets and spices, condiments, and beverages).

Blood and urine collection
--------------------------

Blood was collected in accordance with the standard protocol suggested by the International Zinc Nutrition Consultative Group.[@b28-nmi-8-2015-007] Whole-blood samples were collected from participants (*n* = 48) in seated position at baseline and endpoint in a trace mineral--free tube containing ethylene diamine tetraacetic acid (EDTA) (Sarstedt Inc., Newton, NC, USA) by venipuncture using butterfly needles (Sarstedt, Inc.) after an overnight fast of at least 10 h. On the same morning as blood collection, urine samples were collected in plastic cups, transferred to plastic tubes and stored at −20°C (Falcon, Becton Dickinson Labware, NJ, USA).

Total RNA preparation
---------------------

Whole blood was immediately processed for the isolation of PBMCs. PBMCs were isolated using a density gradient (NycoPrep™ 1.007; Axis-Shield, Norton, MA, USA) in 15-mL conical tubes. Anticoagulated whole blood (3 mL) was diluted with 3 mL of 0.9% NaCl. The 6 mL of diluted blood was carefully poured on 3 mL of the separation gradient in a 15-mL conical tube. The tube was centrifuged at 800× *g* for 30 min at ambient temperature. The PBMC layer formed at the interface between plasma and the separation medium was transferred to a 1.5-mL microfuge tube. The PBMCs from individual samples were washed twice with Dulbecco's phosphate-buffered saline (PBS) (Ca and Mg free) (Sigma-Aldrich Inc, St. Louis, MO, USA), suspended in RNAlater (Life Technologies, Carlsbad, CA, USA), and stored at −20°C prior to being shipped frozen to Oklahoma State University.

Total RNA was isolated from PBMCs using STAT-60 according to the manufacturer's instructions (Tel-Test, Inc., Friendswood, TX, USA). The RNA concentration and integrity were determined using a NanoDrop spectrophotometer (Thermo Fisher Scientific, Middletown, VA, USA) and agarose gel electrophoresis, respectively. Samples generating A~260~:A~280~ ratios within the range of 1.8--2.2 were used to synthesize cDNA. Prior to cDNA synthesis, total RNA (1 μg) was treated with DNase I (Roche Diagnostics, Indianapolis, IN, USA), reverse-transcribed using SuperScript II (Invitrogen, Grand Island, NY, USA), and brought to a final volume of 100 μL.

Gene expression analysis by real-time quantitative polymerase chain reaction
----------------------------------------------------------------------------

For gene expression analyses by qPCR using SYBR green chemistry on an ABI 7900HT system (Applied Biosystems, Grand Island, NY), cDNA was prepared as described above. Primers for qPCR were designed using Primer Express v 3.0 (Applied Biosystems) and validated if they met the following criteria: (1) single peak on dissociation curve and (2) amplification efficiency slope of approximately −3.3 using a titrated standard curve. Additionally, whenever possible, primers were designed such that the amplicon spanned at least one intron. Relative quantitation of *ZnT1*, *ZIP3*, *ZIP4*, *ZIP8*, and *MT1* mRNA abundance was determined using the 2^−ΔΔCt^ method (Applied Biosystems User Bulletin \#2) with Cyclophilin B (Cyclo) as the invariant control. Oligonucleotide primers were obtained from Integrated DNA Technologies (IDT, Inc. Coralville, IO, USA) and their nucleotide sequences are presented in [Tables 1](#t1-nmi-8-2015-007){ref-type="table"} and [2](#t2-nmi-8-2015-007){ref-type="table"}.

Plasma and urine zinc and CRP determinations
--------------------------------------------

Whole blood collected in a tube containing anticoagulant (EDTA) was centrifuged for 10 min within 2 h at \~1000× *g* at ambient temperature to obtain plasma. Plasma was transferred to trace mineral--free microtubes (Sarstedt, Inc.), frozen at −20°C and shipped to Oklahoma State University for analysis. Plasma and urine zinc were analyzed using inductively coupled plasma mass spectrometry (ICP-MS, Elan 9000, Perkin Elmer Life and Analytical Sciences, Norwalk, CT, USA). For ICP-MS analyses, 200 μL plasma was mixed with 3.8 mL of 0.1% nitric acid (GFS Chemicals, Powell, OH, USA) containing 0.01% Triton X-100 (octyl phenoxy polyethoxyethanol, Sigma-Aldrich, Inc). For urine zinc analyses, 500 μL urine was mixed with 4.5-mL 0.1% nitric acid. For plasma as well as urine, internal standard (Gallium, Perkin Elmer Life and Analytical Sciences, Shelton, CT, USA) and external serum standards were used for quality control (Utak Laboratories Inc., Valencia, CA, USA). The reference cut-off for fasting (morning) plasma zinc for a population of adult women was used with \>700 μg/L considered to be normal.[@b26-nmi-8-2015-007] Plasma high-sensitivity CRP (hsCRP) was assessed by enzyme-linked immunosorbent assay (Helica Biosystems, Inc., Fullerton, CA, USA). The optical density was measured at 450 nm using a plate reader (Synergy HT, BioTek Instruments, Inc., Winooski, VT, USA). Plasma CRP concentrations of \<3.8 μg/mL were considered normal.

Statistics
----------

SPSS software version 20.0 (IBM-SPSS) was used for statistical analyses. All data including participant characteristics are described using mean ± standard deviation (SD) unless otherwise indicated. Analysis of variance was used to compare values between groups, and paired *t* tests were used for within-group comparisons between baseline and endpoint after zinc supplementation as well as intraindividual variation in zinc transporter mRNA abundance over time. Bivariate Pearson correlation coefficients were used to describe correlations between zinc transporter mRNA abundance and plasma zinc. Linear regression models were constructed to explore associations between plasma zinc concentrations and zinc transporter gene expression. Statistical significance was set at *P* \< 0.05.

Results
=======

Baseline characteristics of the participants
--------------------------------------------

There were no significant differences at baseline in participant characteristics analyzed by group ([Table 3](#t3-nmi-8-2015-007){ref-type="table"}). The average age of the participants was 33 ± 5 years, and there were 6.9 ± 2.6 members in each household. Nearly half (44.9%) of the participating women and 24.5% of their spouses had no formal education. The maximum level of education attained by a woman was sixth grade. The mean DD score was 4.5 ± 1.0 with a consumption range of two to seven of the 12 food categories. Very few participants reported consuming beef (8%) or mutton (2%) as frequently as once per week. None of the participants had consumed meat in the 24 h prior to blood collection (data not shown). Neither zinc nor iron supplements were taken by the participants prior to the study.

Change in zinc transporter and MT mRNA abundance
------------------------------------------------

Although biological samples were collected from each participant, not all RNA isolated from these samples met minimum standards for analysis by qPCR; thus, data were analyzed using only matching pairs of baseline and endpoint samples from each treatment group that met minimum criteria (*n* = 6--9). For these matching pairs from baseline and endpoint, mRNA abundance for zinc transporters *ZnT1*, *ZIP3*, *ZIP4*, and *ZIP8* and for *MT1* was determined by qPCR. For both groups, the abundance of zinc transporter mRNA did not significantly differ at baseline. After 23 days of zinc supplementation, there was a significant decrease in mean mRNA abundance of *ZIP4* (*P* = 0.036) and *ZIP8* (*P* = 0.038) ([Fig. 1](#f1-nmi-8-2015-007){ref-type="fig"}). However, the mean expression of *ZnT1*, *ZIP3*, and *MT1* mRNAs did not change significantly between the two time points, with *P*-values ranging from 0.10 for *ZnT1* to 0.41 for *ZIP3*. In the placebo group, there was no difference (between baseline and endpoint) in mRNA abundance for any zinc transporter or for *MT1* ([Fig. 1](#f1-nmi-8-2015-007){ref-type="fig"}). Likewise, there was no significant correlation (*P* = 0.18--0.97) between plasma zinc and the mRNA abundance of any of the individual zinc transporters or *MT1* after zinc supplementation.

Plasma and urine zinc and CRP concentrations
--------------------------------------------

Plasma zinc was analyzed at baseline and endpoint ([Table 4](#t4-nmi-8-2015-007){ref-type="table"}). At baseline, for all participants, plasma zinc concentration ranged from 538 to 928 μg/L (*n* = 47). From these, 46.8% (54.2% in the zinc group \[*n* = 24\] and 39.0% in the placebo group \[*n* = 23\]) exhibited plasma zinc concentrations below 700 μg/L, the suggested lower cut-off for assessing adequacy of zinc status.[@b26-nmi-8-2015-007] Despite the random assignment of participants to each treatment group, plasma (*P* = 0.038) and urinary (*P* = 0.02) zinc concentrations were higher in the placebo group at baseline. There was not a significant difference in the placebo group between baseline and the end of the 23-day supplementation for plasma (*P* = 0.31) or urine (*P* = 0.07). However, within the zinc-supplemented group, there was a significant increase in both plasma (*P* \< 0.014) and urinary (*P* = 0.013) zinc concentrations from baseline to the end of treatment. After zinc supplementation, the proportion of women in the zinc group with plasma zinc above 700 μg/L increased significantly from 45.8% to 62.5%.

Concentrations of plasma hsCRP between and within groups were not significantly different at either baseline or endpoint. Fewer than 9% of woman at either time point had slightly elevated hsCRP concentrations (4--9.5 mg/L) but omitting these women had no effect on plasma and urinary zinc.

Discussion
==========

Zinc has been recognized as an important micronutrient for many different functions in the human body. However, more than 50 years after recognition of the importance of zinc for humans, a sensitive and specific biomarker to assess zinc status has not been identified.[@b29-nmi-8-2015-007],[@b30-nmi-8-2015-007] Indeed, there are a variety of measures currently used by investigators to assess an individual's zinc status.[@b31-nmi-8-2015-007]

Zinc transporter proteins are thought to play critical roles in the regulation of intracellular zinc concentrations in mammalian cells through the control of transport across the plasma membrane or from intracellular organelles/compartments. The *ZnT* family of zinc transporters decreases cytoplasmic zinc concentrations by increasing the secretion, sequestration, or efflux of zinc between extracellular and intracellular compartments. The ZIP family of zinc transporters increases intracellular zinc level by influx or release of stored zinc from extracellular space into the cytoplasm.[@b4-nmi-8-2015-007] Therefore, it has been hypothesized that the expression of the *ZnT* mRNA would be increased, whereas the *ZIP* mRNA would be decreased when dietary zinc intake increases.[@b29-nmi-8-2015-007],[@b32-nmi-8-2015-007]

In the present study, PBMCs were stored and frozen in RNAlater prior to being shipped from Ethiopia to the Nutritional Sciences Laboratories at the Oklahoma State University. Although not all samples yielded high-quality RNA, there was sufficient RNA from matched samples to compare zinc transporter mRNA abundance for *ZnT1*, *ZIP3*, *ZIP4*, and *ZIP8* and for *MT1* by qPCR. Others have shown recovery of mRNA from both cell and tissue samples stored in RNAlater solution to be of similar quality compared to frozen samples.[@b33-nmi-8-2015-007],[@b34-nmi-8-2015-007]

*ZIP4* is among the most studied zinc transporters for understanding its key role in maintaining systemic zinc homeostasis in humans. Consistent with its role in modulating zinc uptake, tissues involved in the acquisition of zinc from the diet (ie, by the absorptive intestinal epithelial cell) or from the extracellular space, have relatively abundant *ZIP4* expression. Despite some understanding of the role of *ZIP4* in modulating zinc transport, the detailed mechanisms of the regulation and expression of *ZIP4* among different tissues or cell types is not fully characterized.[@b7-nmi-8-2015-007] In our study, *ZIP4* mRNA abundance from PBMCs decreased significantly after the 23-day zinc supplementation. Other investigators have demonstrated that the expression of *ZIP4* mRNA and protein is downregulated at transcriptional and posttranslational levels in response to zinc availability.[@b35-nmi-8-2015-007]--[@b37-nmi-8-2015-007]

Similarly, *ZIP8* mRNA abundance decreased after the 23-day zinc supplementation. In rat H4IIE cells (a differentiated rat liver cell line) treated with the zinc chelating agent, TPEN (N,N,N',N'-tetrakis (2-pyridylmethyl) ethylenediamine), zinc deficiency alone did not increase *ZIP8* levels, whereas treatment with iron increased the level of *ZIP8*. As a result of the observation that *ZIP8* expression increases in response to iron loading but not zinc depletion, investigators have suggested that the effect might be mediated through a secondary zinc deficiency induced by the high-iron treatment.[@b38-nmi-8-2015-007] In a 24-day zinc depletion--repletion (acclamation 10.4 mg/d for 7 days; depletion \<0.5 mg/d for 10 days, and repletion 15 mg/d for 7 days with habitual diet) study of healthy young men (*n* = 9), the mRNA expression of zinc transporters *ZnT1* and *ZIP8* in erythrocytes did not change significantly due to dietary zinc depletion. Also, in contrast to our finding, *ZIP8* measured in only three subjects was not changed at the end of zinc depletion.[@b39-nmi-8-2015-007]

Gene abundance profiles were assessed for zinc transporters *ZnT1*, *ZIP3*, *ZIP4*, *ZIP8*, and *MT1* quantified from PBMC samples in the present study. However, in stepwise regression analyses, plasma zinc variability was not explained by mRNA abundance of these zinc transporters or *MT1*. Similarly, in a study of 40 healthy adult women and men, aged 21--65 years, with adequate zinc intakes, Foster and colleagues, reported the absence of correlation between dietary or plasma zinc with the abundance of any of the measured individual zinc transporters (*ZnT1*, *ZnT5*, *ZnT7*, *ZnT8*, *ZIP1*, *ZIP3*, *ZIP7*, and *ZIP10*).[@b14-nmi-8-2015-007] Plasma zinc has a high fractional turnover rate,[@b40-nmi-8-2015-007] and information on the factors that trigger influx and efflux of zinc from cellular compartments, as well as the pattern by which intracellular zinc is preferentially maintained in different tissues, is limited.[@b14-nmi-8-2015-007] Thus, adaptations of mRNA expression patterns and plasma zinc concentrations in response to zinc intake may vary in different tissues.

Human studies have demonstrated a decrease in abundance of *ZnT1* mRNA in association with high zinc intake. The increase in *ZnT1* mRNA abundance is consistent with the roles of *ZnT1* in regulating zinc efflux from cells.[@b12-nmi-8-2015-007] Although we did not observe a significant increase in mRNA abundance for *ZnT1* in response to zinc supplementation, *ZnT1* mRNA abundance tended to increase at endpoint. Using monocytes, T lymphocytes, and granulocytes, Aydemir and colleagues,[@b12-nmi-8-2015-007] found that compared to placebo, supplementation with 15 mg/d zinc for 10 days to young male subjects consuming adequate dietary zinc produced an increase in *ZnT1* and *MT1* and a decrease in *ZIP3* mRNA abundance for these leukocyte subsets. However, in an investigation of the abundance of *ZnT1* and *ZIP6* in PBMCs from pulmonary tuberculosis patients (mean serum zinc 56.8 ± 17.1 μg/dL) and healthy controls (97.7 ± 15.9 μg/dL), *ZnT1* did not differ between the two groups[@b41-nmi-8-2015-007] regardless of the significant difference in the serum zinc concentration. In a short-term study of zinc effects on transporters from PBMCs from healthy adults (*n* = 9), *ZIP3* remained unchanged, whereas *ZnT1* and *MT1* mRNA levels significantly decreased with 0.3 mg/d zinc supplementation for 10 days.[@b9-nmi-8-2015-007]

Sample handling environment, storage time, or sample type may partially explain the differences in our study and some reports in the literature. For instance, differences in transporter gene expression were observed when whole blood and isolated leukocytes were compared.[@b42-nmi-8-2015-007] Different outcomes may also be due to variation in RNA stabilization and isolation technique for the evaluation of gene abundance in these types of samples.[@b43-nmi-8-2015-007] In a previous study that found significant positive correlations between a number of zinc transporters, the PBMCs were obtained from 40 individuals with an adequate dietary zinc intake and were processed immediately.[@b14-nmi-8-2015-007] Also zinc transporter mRNA levels from leukocyte subsets of PBMCs analyzed immediately from zinc-supplemented (15 mg/d for 10 days) young men demonstrated an increase in expression pattern of *ZnT1* and *MT1* and a decrease in *ZIP3*.[@b12-nmi-8-2015-007] In the present study, the PBMCs were stored in RNAlater for \~3 months at −20°C, which might contribute to an overall decrease in RNA concentration.

Biological differences between study populations also might be a significant factor between studies evaluating effects of acute and chronic zinc deficiency. Lack of significant change in *MT1* and zinc transporter *ZnT1*, *ZIP3*, and mRNA expression over the study period might suggest interrelationships between the plasma membrane and intracellular membrane zinc transporter mRNA expression patterns that maintain cellular zinc homeostasis, possible adaptations in response to conditions of chronic zinc deficiency.[@b14-nmi-8-2015-007] Typically, the mean dietary zinc intake for pregnant women in the study area was 5 mg/d,[@b20-nmi-8-2015-007] and our participants consumed a similar plant-based diet with very limited amounts of animal source foods.

Plasma zinc is a small proportion of the total body zinc pool which is regulated homeostatically within a narrow range and adapts to a range of zinc intakes resulting in its lack of sensitivity and specificity as a biomarker.[@b13-nmi-8-2015-007],[@b40-nmi-8-2015-007],[@b44-nmi-8-2015-007] Despite this challenge, plasma zinc remains the most widely used biomarker of zinc status.[@b13-nmi-8-2015-007],[@b44-nmi-8-2015-007],[@b45-nmi-8-2015-007] Hair and urine have not been considered reliable indicators of zinc status, and zinc metal-loenzyme activities (alkaline phosphatase, 5-nucleotidase, and erythrocyte and plasma superoxide dismutase) are limited in their utility to function as indicators of zinc status.[@b13-nmi-8-2015-007],[@b44-nmi-8-2015-007]

At the end of the zinc supplementation in the present study, the percentage of women who remained in the low-zinc category was reduced from 54.2% to 37.5% in the zinc-supplemented group, whereas the proportion (39.1%) of women remaining below 700 μg/L did not change in the placebo group. The decrease in proportion of women below the cut-off level in the zinc-supplemented group might indicate a transient increase in plasma zinc due to supplementation after prolonged inadequate dietary zinc intake; however, these women all had BMIs greater than 18.5. Unlike the current study, zinc supplementation of adult women with a BMI range of 16.5--24.1 for 17 days with 20 mg zinc (as ZnSO~4~) in rural Sidama, Ethiopia, did not result in significant change in plasma zinc concentration.[@b46-nmi-8-2015-007]

Our calculated urinary zinc after zinc supplementation was comparable to the mean (SD) reference of 301.5 μg/L (253.9 μg/L) reported in a previous study, which examined representative ranges of reference values for trace minerals in urine.[@b47-nmi-8-2015-007] However, other studies have found both higher and lower urinary zinc excretion values.[@b48-nmi-8-2015-007],[@b49-nmi-8-2015-007]

Strengths of the current study are that mRNA abundance may represent a biomarker of zinc status and that we were able to collect and utilize samples from women living in a remote area with widespread chronic zinc depletion. Although the number of samples available for analysis of zinc transporters was less than those for plasma zinc, the data provide important information for future studies. Improved cell separation, storage, and transport conditions may improve preservation of samples.

Conclusion
==========

In conclusion, an ideal biomarker for zinc status has not yet been determined. In our study of women with chronically low zinc intake, the significant decrease in *ZIP4* and *ZIP8* mRNA abundance with zinc supplementation was biologically plausible. Our results, as well as indications in the literature that particular zinc transporters are regulated by zinc intake support the need for further research to determine mRNA abundance for specific zinc transporters in order to identify potential zinc biomarkers in humans.[@b29-nmi-8-2015-007],[@b50-nmi-8-2015-007] This study provides a basis to further investigate zinc transporter mRNA abundance to assess chronic zinc deficiency, reducing the challenges associated with depletion--repletion studies conducted in a laboratory environment.
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###### 

Reference gene symbols and accession numbers.

  GENE NAME                                    GENE SYMBOL   ACCESSION NUMBER   AMPLICON SIZE
  -------------------------------------------- ------------- ------------------ ---------------
  SLC30A1                                      *ZNT1*        NM_021194          93
  SLC39A3                                      *ZIP3*        NM_144564          66
  SLC39A4                                      *ZIP4*        NM_130849          79
  SLC39A8                                      *ZIP8*        NM_001135147       65
  Metallothionein                              *MT1G*        NM_005950          67
  Peptidylprolyl isomerase B (cyclophilin B)   *PPIBb*       NM_000942          56

###### 

Primer sequences for reference gene analyses by qPCR.

  GENE SYMBOL   FORWARD PRIMER              REVERSE PRIMER
  ------------- --------------------------- -------------------------
  *ZNT1*        5′ TCACCACTTCTGGGGTTTTC     5′ ACCAGGAGGAGACCAACACC
  *ZIP3*        5′ TGTGAGGGAAAAGCTCCAGAAG   5′ TTCGGCCAGCGGGTAGT
  *ZIP4*        5′ ATGTCAGGAGCGGGTCTTGC     5′ GCTGCTGTGCTGCTGGAAC
  *ZIP8*        5′ AATAGGGACGATTGCCTGGAT    5′ GCCAGGCCATCGATGAAAT
  *MT1G*        5′ GCACCTCCTGCAAGAAGAGCT    5′ GCAGCCTTGGGCACACTT
  *PPIB*        5′ TGCCATCGCCAAGGAGTAG      5′ TGCACAGACGGTCACTCAAA

###### 

Baseline characteristics of the participant women in rural Sidama, southern Ethiopia, in June 2012.

  VARIABLE             UNIT      PLACEBO     ZINC SUPPLEMENT
  -------------------- --------- ----------- -----------------
  Age                  Years     33 ± 5      33 ± 5
  Height               m         1.6 ± 0.1   1.6 ± 0.1
  Weight               kg        53 ± 6      51 ± 5
  BMI                  kg/m^2^   21 ± 2      20 ± 2
  Number of children             5 ± 2       4 ± 2

**Note:** Data are expressed as mean ± SD; *n* = 24 in each group.

###### 

Plasma and urinary zinc concentrations of adult women in rural Sidama, southern Ethiopia after 23 days of placebo or zinc supplementation.

                      *n*          PLASMA ZINC (μg/L)        BASELINE TO ENDPOINT                                      
  ------------------- ------------ ------------------------- --------------------------------------------------------- -------------
  Placebo             23           741 ± 92^a^               717 ± 100                                                 *P* = 0.31
  (543--928)          (521--931)                                                                                       
  Zn supplemented     24           680 ± 110^b^              735 ± 80[\*](#tfn3-nmi-8-2015-007){ref-type="table-fn"}   *P* = 0.014
  (538--897)          (597--893)                                                                                       
                                   **URINARY ZINC (μg/L)**                                                             
  Placebo             24           280 ± 135^a^              233 ± 131                                                 *P* = 072
  (105--615)          (34--530)                                                                                        
  Zinc supplemented   24           201 ± 118^b^              289 ± 184\*                                               *P* = 0.013
  (80--609)           (46--782)                                                                                        

**Notes:** Data are expressed as mean ± SD (range). Different letters within a column indicate difference between groups, *P* \< 0.05.

Indicates significant difference between baseline and endpoint.
